Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Gilead Seeks New CEO, Second Quarter Shows Stability

Executive Summary

Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.

You may also be interested in...



Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements

Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.

Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain

Building manufacturing capacity, educating physicians, and reaching agreements with pricing and reimbursement bodies are just some of the hurdles CAR-T therapies have to jump over in Europe, following their approval by the EU Commission earlier this week.

AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133377

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel